Full-Time
Icon
10,001+ employees
Consulting and development services for pharmaceuticals
No salary listed
Entry, Junior
Company Does Not Provide H1B Sponsorship
San Antonio, TX, USA
100% On-Site in San Antonio, TX.
- Bachelor's degree in business administration, human resources, or a related field.
- Phase 1 clinical research experience
- Strong analytical skills with the ability to interpret data, identify trends, and make informed decisions.
- Excellent communication skills, with the ability to collaborate effectively across teams.
- Detail-oriented with strong organizational skills and the ability to prioritize tasks effectively.
- Proficiency in Microsoft Office Suite and other relevant software applications.
- Collaborating with project managers to assess resource needs, staffing needs, and requirements for clinical trials and other projects.
- Assisting in the development of comprehensive resource allocation plans to optimize personnel utilization and ensure project success.
- Monitoring resource availability and utilization across projects, identifying potential bottlenecks or constraints, and proposing solutions to mitigate risks.
- Providing support and assistance to senior resource management staff in various resource planning activities.
- Contributing to the continuous improvement of resource management processes and systems.
Icon provides consulting, development, and commercialization services to help clients accelerate the creation of drugs and medical devices. Their services are designed to improve the quality of life by ensuring that these products reach the market efficiently. Icon operates a global network of offices in 53 countries, allowing them to offer localized support while maintaining high standards of quality. They focus on key factors such as reducing time to market, lowering costs, and enhancing quality, setting them apart from competitors who may not have the same level of global expertise or comprehensive service offerings. The goal of Icon is to support clients in bringing life-saving and life-enhancing products to market as quickly and effectively as possible.
Company Size
10,001+
Company Stage
IPO
Headquarters
Ireland
Founded
1990
Simplify's Take
What believers are saying
- Partnership with Mural Health enhances participant experience in clinical trials.
- Increased use of AI optimizes trial methodologies and patient recruitment.
- Recognition as a climate leader boosts ICON's appeal to socially conscious clients.
What critics are saying
- Securities fraud lawsuit may impact investor confidence and financial stability.
- Emerging CROs with advanced technologies pose competitive threats to ICON.
- Challenges in optimizing biomarker technologies could hinder neurodegenerative research competitiveness.
What makes Icon unique
- ICON leverages AI to accelerate biomarker detection in clinical trials.
- The company focuses on patient-centric technologies like Mural Link for trial management.
- ICON is recognized for its strong ESG practices, enhancing its industry reputation.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Paid Vacation
401(k) Retirement Plan
Mental Health Support
Life Insurance
Flexible Work Hours
Company News
ICON Public Limited Company (ICLR), a leading healthcare and pharmaceutical services provider, has been hit by a securities fraud class-action lawsuit.
The law firm Kessler Topaz Meltzer & Check, LLP announced on March 16, 2025, that it has filed a securities fraud class action lawsuit against ICON Public Limited Company (ICLR).
BERWYN, PENNSYLVANIA and DUBLIN, IRELAND, 4 March 2025 - Mural Health Technologies, Inc., a patient-first clinical trial technology company, and ICON plc (NASDAQ: ICLR), a global healthcare intelligence and clinical research organisation, today announce a partnership to utilise the participant management and payments platform, Mural Link. ICON will utilise Mural Link’s innovative functionality related to clinical trial participant payments, tax management, travel and concierge support, site-participant communication tools, and novel reporting and analytics capabilities. “From our very first conversations with ICON, we were highly impressed by their commitment to patient care and innovation,” said Sam Whitaker, CEO of Mural Health. “This partnership represents a shared vision of removing barriers to trial participation and advancing participation financial neutrality, while eliminating the need for site staff to manage highly manual, error-prone, and time-consuming administrative activities.”
Dublin, Ireland – 8 January 2024 – ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders. The findings indicate that, despite recent successes in developing disease modifying treatments for Alzheimer's, persistent challenges that remain in neurodegenerative clinical trials can be mitigated by underutilised trial methodologies. ICON outlines how these innovations, including increased use of biomarkers and innovative trial designs, can be implemented in its new whitepaper: ‘Early, precise and efficient: The methods and technologies advancing Alzheimer’s and Parkinson’s RD’. Biomarkers are one of the most promising tools to identify potential clinical trial participants early in their disease progression. Encouragingly, nearly all respondents (97%) reported using biomarkers to identify patients and over half (59%) are leveraging AI tools to accelerate biomarker detection. Whilst this uptake is promising, biomarkers are not yet being optimised for full implementation
Dublin, Ireland – 18 December 2024 –ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Barry Balfe as Chief Operating Officer (COO).Barry is a long-tenured ICON employee with over 20 years of service and brings extensive leadership experience and capability to the role of COO. He has held a number of leadership roles across both full service and functional solutions at ICON and has very successfully supported the growth of new and existing customer partnerships. His strong focus and track record on operational excellence, quality & delivery will enable the company to deliver greater value to our customers and further enhance our strategy to become the healthcare intelligence partner of choice in the industry.Barry will continue to report to ICON’s Chief Executive Officer, Steve Cutler.“Barry is a vastly experienced leader and has a very strong reputation across the industry” said Steve Cutler, ICON’s CEO “He has successfully led our largest division over the past number of years, creating and sustaining strategic partnerships with customers that have been key to our growth trajectory as a company. I look forward to working closely with Barry to drive further growth across the organisation, as we create value for our customers in delivering their clinical development programs more efficiently.”“It is a privilege to serve as ICON’s Chief Operating Officer,” said Barry Balfe. “I look forward to working with all of our dedicated colleagues around the world as we continue to drive superior innovation, execution and delivery for customers and for patients.”About ICON plcICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations